Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
busulfan + cyclophosphamide + cytarabine + semustine + anti-thymocyte globulin
- Development stage
- Unknown
- Lead developer
- Peking University People's Hospital
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
mBU + CY + ATG is a multi-drug myeloablative conditioning regimen used in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with relapsed or refractory acute leukemia, particularly in the context of HLA-mismatched transplants. Developed and investigated by Peking University People's Hospital, the regimen consists of modified busulfan (mBU), cyclophosphamide (CY), cytarabine (Ara-C), semustine (Me-CCNU), and anti-thymocyte globulin (ATG). The protocol is designed to maximize anti-leukemic activity through the synergistic effects of multiple alkylating agents and DNA synthesis inhibitors, while ATG provides essential T-cell depletion to mitigate the risk of graft-versus-host disease (GVHD). This regimen is frequently studied in combination with decitabine to further enhance its efficacy in high-risk leukemia populations.
- Other names
- modified busulfan + cyclophosphamide + cytarabine + semustine + anti-thymocyte globulinmBU/CY + ATG
02
Targets
DNA polymerase familyDNA
Beyond the preview
Go deeper on busulfan + cyclophosphamide + cytarabine + semustine + anti-thymocyte globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on busulfan + cyclophosphamide + cytarabine + semustine + anti-thymocyte globulin.